<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283686</url>
  </required_header>
  <id_info>
    <org_study_id>DK62401-PKD-TN (IND)</org_study_id>
    <nct_id>NCT00283686</nct_id>
  </id_info>
  <brief_title>HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A</brief_title>
  <official_title>Polycystic Kidney Disease-Treatment Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Polycystic Kidney Disease Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the
      progression of cystic disease and on the decline in renal function in autosomal dominant
      kidney disease (ADPKD) will be assessed in two multicenter randomized clinical trials
      targeting different levels of kidney function: 1) early disease defined by GFR &gt;60
      mL/min/1.73 m2 (Study A); and 2) moderately advanced disease defined by GFR 25-60 mL/min/1.73
      m2 (Study B; NCT01885559). Participants will be recruited and enrolled, either to Study A or
      B, over the first three years. Participants enrolled in Study A will be followed for at least
      5 years, while those enrolled in Study B will be followed for five-to-eight years, with the
      average length of follow-up being six and a half years. The two concurrent randomized
      clinical trials differ by eligibility criteria, interventions and outcomes to be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      * Specific Aims of Study A

      To study the efficacy of angiotensin-converting-enzyme inhibitor (ACE-I) and
      angiotensin-receptor blockade (ARB) combination therapy as compared to ACE-I monotherapy and
      usual vs. low blood pressure targets on the percent change in kidney volume in participants
      with preserved renal function (GFR &gt;60 mL/min/1.73m2)and high-normal blood pressure or
      hypertension (&gt;130/80 mm Hg).

      * Hypotheses to be tested in Study A

      In ADPKD individuals with hypertension or high-normal blood pressure and relatively preserved
      renal function (GFR &gt;60 mL/min/1.73 m2), multi-level blockade of the RAAS using ACE-I/ARB
      combination therapy will delay progression of cystic disease as compared to ACE-I
      monotherapy, and a low blood pressure goal will delay progression as compared with standard
      control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study A: Percent Annual Change in Total Kidney Volume</measure>
    <time_frame>Baseline and 2-, 4- and 5-year follow-up</time_frame>
    <description>Annual percentage change in total kidney volume as assessed by abdominal magnetic resonance imaging (MRI) at baseline, 2 years, 4 years, and 5 years follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney Function (eGFR)</measure>
    <time_frame>Up to 96 months (6 month assessments)</time_frame>
    <description>The estimated GFR was calculated by means of the Chronic Kidney Disease Epidemiology Collaboration equation with the use of central serum creatinine measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>Up to 96 months (assessed annually)</time_frame>
    <description>Urine albumin excretion, centrally processed from 24 hour urine collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>Up to 96 months (assessed annually)</time_frame>
    <description>Urinary aldosterone excretion, centrally processed, 24 hour urine collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Mass Index</measure>
    <time_frame>0, 24 months, 48 months, 60 months</time_frame>
    <description>Left ventricular mass index (g/m^2) measured by MRI, centrally reviewed and measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Blood Flow</measure>
    <time_frame>0, 24 months, 48 months, 60 months</time_frame>
    <description>renal blood flow (mL/min/1.73 m^2) from MRI, centrally reviewed and measured. This outcome was more difficult to measure resulting in more missing data than other MRI outcomes such as total kidney volume (TKV) and left ventricular mass index (LVMI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Hospitalizations</measure>
    <time_frame>Up to 96 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Physical Component Summary</measure>
    <time_frame>baseline, 12, 24, 36, 48, 60, 72, 84, and 96 months (assessed annually)</time_frame>
    <description>Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Mental Component Summary</measure>
    <time_frame>baseline, 12, 24, 36, 48, 60, 72, 84, and 96 months (assessed annually)</time_frame>
    <description>Short Form-36 Quality of LIfe Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">558</enrollment>
  <condition>Kidney, Polycystic</condition>
  <arm_group>
    <arm_group_label>Study A, Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lisinopril + Telmisartan (ACE-I + ARB) and standard blood pressure control of 120-130/70-80 mm Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study A, Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lisinopril + Telmisartan (ACE-I + ARB) and low blood pressure control of 95-110/60-75 mm Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study A, Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lisinopril + Placebo (ACE-I + Placebo) and standard blood pressure control of 120-130/70-80 mm Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study A, Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lisinopril + Placebo (ACE-I + Placebo) and low blood pressure control of 95-110/60-75 mm Hg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Lisinopril titrated to 5mg, 10mg, 20mg, 40mg</description>
    <arm_group_label>Study A, Arm 1</arm_group_label>
    <arm_group_label>Study A, Arm 2</arm_group_label>
    <arm_group_label>Study A, Arm 3</arm_group_label>
    <arm_group_label>Study A, Arm 4</arm_group_label>
    <other_name>ACE-I</other_name>
    <other_name>ACE</other_name>
    <other_name>Ace-Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants</description>
    <arm_group_label>Study A, Arm 1</arm_group_label>
    <arm_group_label>Study A, Arm 2</arm_group_label>
    <other_name>ARB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants</description>
    <arm_group_label>Study A, Arm 3</arm_group_label>
    <arm_group_label>Study A, Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Blood Pressure Control</intervention_name>
    <description>Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator</description>
    <arm_group_label>Study A, Arm 1</arm_group_label>
    <arm_group_label>Study A, Arm 3</arm_group_label>
    <other_name>blood pressure control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Blood Pressure Control</intervention_name>
    <description>Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator</description>
    <arm_group_label>Study A, Arm 2</arm_group_label>
    <arm_group_label>Study A, Arm 4</arm_group_label>
    <other_name>blood pressure control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ADPKD.

          -  Age 15-49 (Study A); Age 18-64 (Study B).

          -  GFR &gt;60 mL/min/1.73 m2 (Study A); GFR 25-60 mL/min/1.73 m2 (Study B).

          -  BP ≥130/80 or receiving treatment for hypertension.

          -  Informed Consent.

        Exclusion Criteria:

          -  Pregnant/intention to become pregnant in 4-6 yrs.

          -  Documented renal vascular disease.

          -  Spot urine albumin-to-creatinine ratio of &gt;0.5 (Study A) or ≥1.0 (Study B) and/or
             findings suggestive of kidney disease other than ADPKD.

          -  Diabetes requiring insulin or oral hypoglycemic agents / fasting serum glucose of &gt;126
             mg/dl / random non-fasting glucose of &gt;200 mg/dl.

          -  Serum potassium &gt;5.5 milliequivalent per liter (mEq/L) for participants currently on
             ACE-I or ARB; &gt;5.0 mEq/L for participants not currently on ACE-I or ARB.

          -  History of angioneurotic edema or other absolute contraindication for ACE-I or ARB.
             Intolerable cough associated with ACE-I is defined as a cough developing within six
             months of initiation of ACE-I in the absence of other causes and resolving upon
             discontinuation of the ACE-I.

          -  Indication (other than hypertension) for β-blocker or calcium channel blocker therapy
             (e.g. angina, past myocardial infarction, arrhythmia), unless approved by the site
             principal investigator. (PI may choose to accept an individual who is on only a small
             dose of one of these agents and would otherwise be eligible.)

          -  Systemic illness necessitating nonsteroidal antiinflammatory drugs (NSAIDs),
             immunosuppressant or immunomodulatory medications.

          -  Systemic illness with renal involvement.

          -  Hospitalized for acute illness in past 2 months.

          -  Life expectancy &lt;2 years.

          -  History of non-compliance.

          -  Unclipped cerebral aneurysm &gt;7mm diameter.

          -  Creatine supplements within 3 months of screening visit.

          -  Congenital absence of a kidney (also total nephrectomy for Study B).

          -  Known allergy to sorbitol or sodium polystyrene sulfonate.

          -  Exclusions specific to magnetic resonance imaging (Study A).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Schrier, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arlene Chapman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Perrone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University-New England Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Torres, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marva Moxey-Mims, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charity G Moore, MS,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver (Aurora)</city>
        <state>Colorado</state>
        <zip>800045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts University-New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pkdcure.org</url>
    <description>Polycystic Kidney Disease Foundation Website</description>
  </link>
  <link>
    <url>http://www.niddk.nih.gov/welcome/welcome.htm</url>
    <description>National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases Website</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2006</study_first_submitted>
  <study_first_submitted_qc>January 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2006</study_first_posted>
  <results_first_submitted>February 9, 2015</results_first_submitted>
  <results_first_submitted_qc>February 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2015</results_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Charity G Moore, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>polycystic kidney disease</keyword>
  <keyword>polycystic</keyword>
  <keyword>kidney</keyword>
  <keyword>disease</keyword>
  <keyword>adpkd</keyword>
  <keyword>halt</keyword>
  <keyword>pkd</keyword>
  <keyword>blood pressure</keyword>
  <keyword>bp</keyword>
  <keyword>hypertension</keyword>
  <keyword>renal</keyword>
  <keyword>renin-angiotensin-aldosterone-system</keyword>
  <keyword>RAAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at seven clinical sites between February 2006 and June 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ACE-I/ARB and Standard BP</title>
          <description>ACE-I + angiotensin-receptor blocker (ARB) and standard blood pressure control of 120-130/70-80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 120-130/70-80 mm Hg.</description>
        </group>
        <group group_id="P2">
          <title>ACE-I/ARB and Low BP</title>
          <description>ACE-I + angiotensin-receptor blocker (ARB) and low blood pressure control of 95-110/60-75 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve low blood pressure control of 95-110/60-75 mm Hg.</description>
        </group>
        <group group_id="P3">
          <title>ACE-I/Placebo and Standard BP</title>
          <description>ACE-I + Placebo and standard blood pressure control of 120-130/70-80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 120-130/70-80 mm Hg.</description>
        </group>
        <group group_id="P4">
          <title>ACE-I/Placebo and Low BP</title>
          <description>ACE-I + Placebo and low blood pressure control of 95-110/60-75 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve low blood pressure control of 95-110/60-75 mm Hg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="144"/>
                <participants group_id="P4" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="111"/>
                <participants group_id="P4" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Less than full participation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACE-I/ARB and Standard BP</title>
          <description>ACE-I + ARB and standard blood pressure control of 120-130/70-80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 120-130/70-80 mm Hg.</description>
        </group>
        <group group_id="B2">
          <title>ACE-I/ARB and Low BP</title>
          <description>ACE-I + ARB and low blood pressure control of 95-110/60-75 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve low blood pressure control of 95-110/60-75 mm Hg.</description>
        </group>
        <group group_id="B3">
          <title>ACE-I/Placebo and Standard BP</title>
          <description>ACE-I + Placebo and standard blood pressure control of 120-130/70-80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 120-130/70-80 mm Hg.</description>
        </group>
        <group group_id="B4">
          <title>ACE-I/Placebo and Low BP</title>
          <description>ACE-I + Placebo and low blood pressure control of 95-110/60-75 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve low blood pressure control of 95-110/60-75 mm Hg.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="144"/>
            <count group_id="B4" value="141"/>
            <count group_id="B5" value="558"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.0" spread="8.3"/>
                    <measurement group_id="B2" value="37.1" spread="8.4"/>
                    <measurement group_id="B3" value="35.8" spread="8.6"/>
                    <measurement group_id="B4" value="36.8" spread="8.0"/>
                    <measurement group_id="B5" value="36.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="131"/>
                    <measurement group_id="B5" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Diagnosis of autosomal dominant polycystic kidney disease (ADPKD)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="10.0"/>
                    <measurement group_id="B2" value="28.5" spread="10.0"/>
                    <measurement group_id="B3" value="27.0" spread="9.5"/>
                    <measurement group_id="B4" value="27.6" spread="10.4"/>
                    <measurement group_id="B5" value="27.6" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m2)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="5.4"/>
                    <measurement group_id="B2" value="27.4" spread="5.1"/>
                    <measurement group_id="B3" value="27.3" spread="5.5"/>
                    <measurement group_id="B4" value="26.8" spread="4.8"/>
                    <measurement group_id="B5" value="27.2" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine (mg/dl)</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="0.3"/>
                    <measurement group_id="B2" value="1.0" spread="0.2"/>
                    <measurement group_id="B3" value="0.9" spread="0.2"/>
                    <measurement group_id="B4" value="1.0" spread="0.2"/>
                    <measurement group_id="B5" value="1.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) eGFR (ml/min/m2)</title>
          <units>ml/min/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.5" spread="18.8"/>
                    <measurement group_id="B2" value="86.5" spread="19.3"/>
                    <measurement group_id="B3" value="92.9" spread="18.5"/>
                    <measurement group_id="B4" value="87.6" spread="17.2"/>
                    <measurement group_id="B5" value="88.9" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PKD Genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PKD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PKD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Mutation Detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No information</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Study A: Percent Annual Change in Total Kidney Volume</title>
        <description>Annual percentage change in total kidney volume as assessed by abdominal magnetic resonance imaging (MRI) at baseline, 2 years, 4 years, and 5 years follow-up.</description>
        <time_frame>Baseline and 2-, 4- and 5-year follow-up</time_frame>
        <population>Analyses were conducted on all participants who had at least one total kidney volume measurement using intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + ARB</title>
            <description>ACE-I plus ARB (Lisinopril plus telmisartan)</description>
          </group>
          <group group_id="O2">
            <title>ACE-I Alone</title>
            <description>ACE-I monotherapy (lisinopril only)</description>
          </group>
          <group group_id="O3">
            <title>Low Blood Pressure Group</title>
            <description>Targeted blood pressure was 95/60 to 110/75 mm Hg</description>
          </group>
          <group group_id="O4">
            <title>Standard Blood Pressure Group</title>
            <description>Targeted blood pressure was 120/70 to 130/80 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Study A: Percent Annual Change in Total Kidney Volume</title>
          <description>Annual percentage change in total kidney volume as assessed by abdominal magnetic resonance imaging (MRI) at baseline, 2 years, 4 years, and 5 years follow-up.</description>
          <population>Analyses were conducted on all participants who had at least one total kidney volume measurement using intention to treat.</population>
          <units>percentage of Total Kidney Volume</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="282"/>
                <count group_id="O3" value="271"/>
                <count group_id="O4" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="5.5" upper_limit="6.4"/>
                    <measurement group_id="O2" value="6.2" lower_limit="5.7" upper_limit="6.7"/>
                    <measurement group_id="O3" value="5.6" lower_limit="5.2" upper_limit="6.1"/>
                    <measurement group_id="O4" value="6.6" lower_limit="6.1" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>adjusted for age, sex, race, baseline estimated GFR, and clinical site.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Test for differences between treatment groups over time.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>adjusted for age, sex, race, baseline estimated GFR, and clinical site.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Testing differences between blood pressure groups over time</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kidney Function (eGFR)</title>
        <description>The estimated GFR was calculated by means of the Chronic Kidney Disease Epidemiology Collaboration equation with the use of central serum creatinine measurements.</description>
        <time_frame>Up to 96 months (6 month assessments)</time_frame>
        <population>Analyses were intention to treat: All participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + ARB</title>
            <description>ACE-I plus ARB (Lisinopril plus telmisartan)</description>
          </group>
          <group group_id="O2">
            <title>ACE-I Alone</title>
            <description>ACE-I monotherapy (lisinopril only)</description>
          </group>
          <group group_id="O3">
            <title>Low Blood Pressure Group</title>
            <description>Targeted blood pressure was 95/60 to 110/75 mm Hg</description>
          </group>
          <group group_id="O4">
            <title>Standard Blood Pressure Group</title>
            <description>Targeted blood pressure was 120/70 to 130/80 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Kidney Function (eGFR)</title>
          <description>The estimated GFR was calculated by means of the Chronic Kidney Disease Epidemiology Collaboration equation with the use of central serum creatinine measurements.</description>
          <population>Analyses were intention to treat: All participants who were randomized.</population>
          <units>ml/min/1.73/m2/yr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="274"/>
                <count group_id="O4" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-3.3" upper_limit="-2.7"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-3.2" upper_limit="-2.6"/>
                    <measurement group_id="O3" value="-2.9" lower_limit="-3.2" upper_limit="-2.6"/>
                    <measurement group_id="O4" value="-3.0" lower_limit="-3.3" upper_limit="-2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>adjusting for age, sex, race, and clinical site</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Testing for differences in treatment over time (differences in slopes over time).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <p_value_desc>adjusted for age, sex, race, and clinical site</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Testing for differences between groups over time (differences in slopes over time)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albuminuria</title>
        <description>Urine albumin excretion, centrally processed from 24 hour urine collection</description>
        <time_frame>Up to 96 months (assessed annually)</time_frame>
        <population>Analysis by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + ARB</title>
            <description>ACE-I plus ARB (Lisinopril plus telmisartan)</description>
          </group>
          <group group_id="O2">
            <title>ACE-I Alone</title>
            <description>ACE-I monotherapy (lisinopril only)</description>
          </group>
          <group group_id="O3">
            <title>Low Blood Pressure Group</title>
            <description>Targeted blood pressure was 95/60 to 110/75 mm Hg</description>
          </group>
          <group group_id="O4">
            <title>Standard Blood Pressure Group</title>
            <description>Targeted blood pressure was 120/70 to 130/80 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Albuminuria</title>
          <description>Urine albumin excretion, centrally processed from 24 hour urine collection</description>
          <population>Analysis by intention to treat</population>
          <units>annual percent change in mg/24 hr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="274"/>
                <count group_id="O4" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-3.1" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-2.3" upper_limit="1.6"/>
                    <measurement group_id="O3" value="-3.8" lower_limit="-5.7" upper_limit="-1.8"/>
                    <measurement group_id="O4" value="2.4" lower_limit="0.5" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusting for age, sex, race, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusting for age, sex, race, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5</ci_lower_limit>
            <ci_upper_limit>-3.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aldosterone</title>
        <description>Urinary aldosterone excretion, centrally processed, 24 hour urine collection</description>
        <time_frame>Up to 96 months (assessed annually)</time_frame>
        <population>Analysis using intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + ARB</title>
            <description>ACE-I plus ARB (Lisinopril plus telmisartan)</description>
          </group>
          <group group_id="O2">
            <title>ACE-I Alone</title>
            <description>ACE-I monotherapy (lisinopril only)</description>
          </group>
          <group group_id="O3">
            <title>Low Blood Pressure Group</title>
            <description>Targeted blood pressure was 95/60 to 110/75 mm Hg</description>
          </group>
          <group group_id="O4">
            <title>Standard Blood Pressure Group</title>
            <description>Targeted blood pressure was 120/70 to 130/80 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Aldosterone</title>
          <description>Urinary aldosterone excretion, centrally processed, 24 hour urine collection</description>
          <population>Analysis using intention to treat</population>
          <units>annual % change micrograms per 24 hr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="274"/>
                <count group_id="O4" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" lower_limit="-9.9" upper_limit="-7.2"/>
                    <measurement group_id="O2" value="-7.3" lower_limit="-8.7" upper_limit="-5.9"/>
                    <measurement group_id="O3" value="-8.5" lower_limit="-9.9" upper_limit="-7.1"/>
                    <measurement group_id="O4" value="-7.3" lower_limit="-8.6" upper_limit="-5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusting for age, sex, race, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusting for age, sex, race, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Mass Index</title>
        <description>Left ventricular mass index (g/m^2) measured by MRI, centrally reviewed and measured</description>
        <time_frame>0, 24 months, 48 months, 60 months</time_frame>
        <population>Analyses were conducted using intention to treat for participants with at least one left ventricular mass index measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + ARB</title>
            <description>ACE-I plus ARB (Lisinopril plus telmisartan)</description>
          </group>
          <group group_id="O2">
            <title>ACE-I Alone</title>
            <description>ACE-I monotherapy (lisinopril only)</description>
          </group>
          <group group_id="O3">
            <title>Low Blood Pressure Group</title>
            <description>Targeted blood pressure was 95/60 to 110/75 mm Hg</description>
          </group>
          <group group_id="O4">
            <title>Standard Blood Pressure Group</title>
            <description>Targeted blood pressure was 120/70 to 130/80 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Mass Index</title>
          <description>Left ventricular mass index (g/m^2) measured by MRI, centrally reviewed and measured</description>
          <population>Analyses were conducted using intention to treat for participants with at least one left ventricular mass index measure.</population>
          <units>annual change in g/m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="265"/>
                <count group_id="O4" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" lower_limit="-1.15" upper_limit="-0.68"/>
                    <measurement group_id="O2" value="-0.83" lower_limit="-1.06" upper_limit="-0.59"/>
                    <measurement group_id="O3" value="-1.17" lower_limit="-1.41" upper_limit="-0.93"/>
                    <measurement group_id="O4" value="-0.57" lower_limit="-0.80" upper_limit="-0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for age, sex, race, baseline estimated GFR, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.088</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>comparing the annual change over time between ACE/ARB and ACE alone</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for age, sex, race, baseline estimated GFR, and clinical site</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
            <estimate_desc>comparing annual change in LVMI between Low Blood Pressure and Standard Blood Pressure groups</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Blood Flow</title>
        <description>renal blood flow (mL/min/1.73 m^2) from MRI, centrally reviewed and measured. This outcome was more difficult to measure resulting in more missing data than other MRI outcomes such as total kidney volume (TKV) and left ventricular mass index (LVMI).</description>
        <time_frame>0, 24 months, 48 months, 60 months</time_frame>
        <population>Analyses were conducted using intention to treat analyses for participants with at least one valid renal blood flow measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + ARB</title>
            <description>ACE-I plus ARB (Lisinopril plus telmisartan)</description>
          </group>
          <group group_id="O2">
            <title>ACE-I Alone</title>
            <description>ACE-I monotherapy (lisinopril only)</description>
          </group>
          <group group_id="O3">
            <title>Low Blood Pressure Group</title>
            <description>Targeted blood pressure was 95/60 to 110/75 mm Hg</description>
          </group>
          <group group_id="O4">
            <title>Standard Blood Pressure Group</title>
            <description>Targeted blood pressure was 120/70 to 130/80 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Blood Flow</title>
          <description>renal blood flow (mL/min/1.73 m^2) from MRI, centrally reviewed and measured. This outcome was more difficult to measure resulting in more missing data than other MRI outcomes such as total kidney volume (TKV) and left ventricular mass index (LVMI).</description>
          <population>Analyses were conducted using intention to treat analyses for participants with at least one valid renal blood flow measure.</population>
          <units>annual change in mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" lower_limit="-11.0" upper_limit="-2.1"/>
                    <measurement group_id="O2" value="-9.5" lower_limit="-14.0" upper_limit="-5.1"/>
                    <measurement group_id="O3" value="-7.6" lower_limit="-12.0" upper_limit="-3.1"/>
                    <measurement group_id="O4" value="-8.5" lower_limit="-13.0" upper_limit="-4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for age, sex, race, baseline estimated GFR, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.55</ci_lower_limit>
            <ci_upper_limit>8.50</ci_upper_limit>
            <estimate_desc>difference in annual change in mL/min/1.73 m^2 for ACE+ARB compared to ACE alone</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusting for age, sex, race, baseline estimated GFR, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.54</ci_lower_limit>
            <ci_upper_limit>6.50</ci_upper_limit>
            <estimate_desc>difference in annual change mL/min/1.73 m^2 between low and standard blood pressure groups</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-Cause Hospitalizations</title>
        <time_frame>Up to 96 months</time_frame>
        <population>Intention to treat analysis: All participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + ARB</title>
            <description>ACE-I plus ARB (Lisinopril plus telmisartan)</description>
          </group>
          <group group_id="O2">
            <title>ACE-I Alone</title>
            <description>ACE-I monotherapy (lisinopril only)</description>
          </group>
          <group group_id="O3">
            <title>Low Blood Pressure Group</title>
            <description>Targeted blood pressure was 95/60 to 110/75 mm Hg</description>
          </group>
          <group group_id="O4">
            <title>Standard Blood Pressure Group</title>
            <description>Targeted blood pressure was 120/70 to 130/80 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>All-Cause Hospitalizations</title>
          <population>Intention to treat analysis: All participants who were randomized.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="285"/>
                <count group_id="O3" value="274"/>
                <count group_id="O4" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0228</p_value>
            <method>Regression, Cox</method>
            <method_desc>adjusting for age, sex, race, and clinical site</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Regression, Cox</method>
            <method_desc>adjusting for age, sex, race, and clinical site</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Physical Component Summary</title>
        <description>Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome)</description>
        <time_frame>baseline, 12, 24, 36, 48, 60, 72, 84, and 96 months (assessed annually)</time_frame>
        <population>Analysis using intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + ARB</title>
            <description>ACE-I plus ARB (Lisinopril plus telmisartan)</description>
          </group>
          <group group_id="O2">
            <title>ACE-I Alone</title>
            <description>ACE-I monotherapy (lisinopril only)</description>
          </group>
          <group group_id="O3">
            <title>Low Blood Pressure Group</title>
            <description>Targeted blood pressure was 95/60 to 110/75 mm Hg</description>
          </group>
          <group group_id="O4">
            <title>Standard Blood Pressure Group</title>
            <description>Targeted blood pressure was 120/70 to 130/80 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Physical Component Summary</title>
          <description>Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome)</description>
          <population>Analysis using intention to treat</population>
          <units>annual change in units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="285"/>
                <count group_id="O3" value="274"/>
                <count group_id="O4" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" lower_limit="-0.37" upper_limit="-0.11"/>
                    <measurement group_id="O2" value="-.23" lower_limit="-.35" upper_limit="-0.10"/>
                    <measurement group_id="O3" value="-0.17" lower_limit="-0.30" upper_limit="-0.03"/>
                    <measurement group_id="O4" value="-0.30" lower_limit="-0.43" upper_limit="-0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusting for age, sex, race, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusting for age, sex, race, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.046</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Mental Component Summary</title>
        <description>Short Form-36 Quality of LIfe Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome)</description>
        <time_frame>baseline, 12, 24, 36, 48, 60, 72, 84, and 96 months (assessed annually)</time_frame>
        <population>Analysis using intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + ARB</title>
            <description>ACE-I plus ARB (Lisinopril plus telmisartan)</description>
          </group>
          <group group_id="O2">
            <title>ACE-I Alone</title>
            <description>ACE-I monotherapy (lisinopril only)</description>
          </group>
          <group group_id="O3">
            <title>Low Blood Pressure Group</title>
            <description>Targeted blood pressure was 95/60 to 110/75 mm Hg</description>
          </group>
          <group group_id="O4">
            <title>Standard Blood Pressure Group</title>
            <description>Targeted blood pressure was 120/70 to 130/80 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Mental Component Summary</title>
          <description>Short Form-36 Quality of LIfe Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome)</description>
          <population>Analysis using intention to treat.</population>
          <units>annual change in units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="285"/>
                <count group_id="O3" value="274"/>
                <count group_id="O4" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.03" upper_limit="0.35"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-0.21" upper_limit="0.10"/>
                    <measurement group_id="O3" value="-0.05" lower_limit="-0.21" upper_limit="0.11"/>
                    <measurement group_id="O4" value="0.18" lower_limit="0.03" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0221</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusting for age, sex, race, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0339</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusting for age, sex, race, and clinical site</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>-0.018</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5-8 years with average follow-up of 5.7 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ACE-I + ARB</title>
          <description>ACE-I plus ARB (Lisinopril plus telmisartan)</description>
        </group>
        <group group_id="E2">
          <title>ACE-I Alone</title>
          <description>ACE-I monotherapy (lisinopril only)</description>
        </group>
        <group group_id="E3">
          <title>Low Blood Pressure Group</title>
          <description>Targeted blood pressure was 95/60 to 110/75 mm Hg</description>
        </group>
        <group group_id="E4">
          <title>Standard Blood Pressure Group</title>
          <description>Targeted blood pressure was 120/70 to 130/80 mm Hg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="274"/>
                <counts group_id="E4" subjects_affected="79" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="273"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ileal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gallbladder obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Joint infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ovarian infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Postoperative hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Musculoskeletal deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Transient ischemic attacks</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, puerperium and perinatal conditions - Other, specify</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="273"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="274"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Unintended pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="273"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Renal calculi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Renal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Reproductive system and breast disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Uterine pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Uterine obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="285"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="274"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="273"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="274"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="273"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="285"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="274"/>
                <counts group_id="E4" events="17" subjects_affected="13" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Arlene Chapman</name_or_title>
      <organization>Emory University</organization>
      <phone>(404) 712‐1993</phone>
      <email>abchapm@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

